Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
23.40
+0.37 (1.61%)
At close: Aug 29, 2025, 4:00 PM
22.94
-0.46 (-1.97%)
After-hours: Aug 29, 2025, 6:47 PM EDT
Tourmaline Bio Employees
Tourmaline Bio had 74 employees as of December 31, 2024. The number of employees increased by 30 or 68.18% compared to the previous year.
Employees
74
Change (1Y)
30
Growth (1Y)
68.18%
Revenue / Employee
n/a
Profits / Employee
-$1,195,595
Market Cap
601.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 74 | 30 | 68.18% |
| Dec 31, 2023 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TRML News
- 17 days ago - Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha
- 3 months ago - Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - GlobeNewsWire
- 4 months ago - Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 months ago - Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 months ago - Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire
- 8 months ago - Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker - GlobeNewsWire
- 9 months ago - Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day - GlobeNewsWire